1. Home
  2. PVLA
  3. PVLA News

Latest Palvella Therapeutics Inc. Common Stock (PVLA) News on April 2, 2025

PVLA

GuruFocus.com

a day ago

Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
PVLA

GlobeNewswire

2 days ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
PVLA

GlobeNewswire

15 days ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well
PVLA

Simply Wall St.

17 days ago

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well

Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025
PVLA

Insider Monkey

a month ago

Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
PVLA

GlobeNewswire

a month ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls
PVLA

TipRanks

a month ago

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
PVLA

GlobeNewswire

2 months ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
PVLA

GlobeNewswire

3 months ago

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
PVLA

GlobeNewswire

3 months ago

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

Palvella Therapeutics initiated with a Buy at H.C. Wainwright
PVLA

TipRanks

3 months ago

Palvella Therapeutics initiated with a Buy at H.C. Wainwright

Share on Social Networks: